Sponsor Directory

Genentech, Inc. clinical trials

Sponsor pages show live ClinicalTrials.gov search results and objective aggregate stats only. They do not describe sponsor quality, reputation, or expected outcomes.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 6:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1397

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Alzheimer's Disease
Interventions: Semorinemab, Placebo, [18F]GTP1; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 50 Years to 80 Years
Enrollment: 457 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 43
States / cities: Birmingham, Alabama • Glendale, California • Irvine, California + 39 more

Conditions: Moderate-to-severe Allergic Asthma
Interventions: Omalizumab; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 12
States / cities: Rolling Hills Estates, California • Denver, Colorado • Pembroke Pines, Florida + 9 more

Conditions: Non-Hodgkins Lymphoma
Interventions: Cyclophosphamide, Mitoxantrone, Vincristine, Prednisone, Rituximab; Drug
Lead sponsor: SCRI Development Innovations, LLC; Other
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2010
U.S. locations: 2
States / cities: Fort Myers, Florida • Nashville, Tennessee

Conditions: Esophageal Cancer
Interventions: Erlotinib, Bevacizumab, Paclitaxel, Carboplatin, 5-FU, Radiation therapy, Surgery; Drug · Procedure
Lead sponsor: SCRI Development Innovations, LLC; Other
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 9
States / cities: Fort Myers, Florida • Jacksonville, Florida • Gainesville, Georgia + 6 more

Conditions: Gastric Cancer
Interventions: 5-Fluorouracil, Ipatasertib, Leucovorin, Oxaliplatin, Placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 3
States / cities: Los Angeles, California • Boston, Massachusetts • Houston, Texas

Conditions: Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma
Interventions: ABT-199; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 222 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2020
U.S. locations: 8
States / cities: Tucson, Arizona • La Jolla, California • Boston, Massachusetts + 4 more

Conditions: Severe Persistent Asthma
Interventions: Not listed
Lead sponsor: Rush University Medical Center; Other
Eligibility: 12 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Severe Acute Respiratory Syndrome, Respiratory Failure, Acute Respiratory Distress Syndrome
Interventions: Alteplase 50 MG [Activase]; Drug
Lead sponsor: Denver Health and Hospital Authority; Other
Eligibility: 18 Years to 75 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 9
States / cities: La Jolla, California • Aurora, Colorado • Denver, Colorado + 5 more

Conditions: Breast Cancer
Interventions: Bevacizumab, Cyclophosphamide, Methotrexate, Lifestyle: Diet, Lifestyle: Diet+Exercise; Drug · Behavioral
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2019
U.S. locations: 9
States / cities: Birmingham, Alabama • Indianapolis, Indiana • Boston, Massachusetts + 5 more

Conditions: Neoplasms
Interventions: 5-FU, Docetaxel, Enzalutamide, Ipatasertib, Leucovorin, Oxaliplatin, Paclitaxel; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2020
U.S. locations: 7
States / cities: San Francisco, California • Sarasota, Florida • Boston, Massachusetts + 4 more

Conditions: COVID-19 Pneumonia
Interventions: MSTT1041A, MSTT1041A-matched Placebo, UTTR1147A, UTTR1147A-matched Placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 396 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 24
States / cities: Little Rock, Arkansas • Chula Vista, California • La Mesa, California + 20 more

Conditions: Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
Interventions: Ibrutinib, Obinutuzumab; Drug · Biological
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Portland, Oregon

About this Genentech, Inc. sponsor directory page

What this page lists: U.S. ClinicalTrials.gov public records where Genentech, Inc. is the lead sponsor, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by condition, intervention, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Genentech, Inc. trials.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, sponsor quality scoring, ranking of trials, or AI-generated medical summaries.

Genentech, Inc. clinical trials

Filter and sort this sponsor

Live official records

A Study to Evaluate the Efficacy and Safety of Semorinemab in Patients With Prodromal to Mild Alzheimer's Disease

A Study to Assess the Impact of Omalizumab on Exercise Capacity, Physical Activity, and Sleep Quality in Participants With Moderate to Severe Allergic Asthma

Combination Chemotherapy and Rituximab With Pegfilgrastim Followed by Rituximab, in Large B-Cell Non-Hodgkin's Lymphoma

Chemotherapy, Radiation Therapy and Immunotherapy Prior to Surgery in Operable Esophageal Cancer

A Study of Ipatasertib (GDC-0068) in Combination With Fluoropyrimidine Plus Oxaliplatin in Participants With Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer

A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma

Identification of Serum Biomarkers for CD15+ Hypodense Neutrophils in Severe Asthma

Fibrinolytic Therapy to Treat ARDS in the Setting of COVID-19 Infection

Bevacizumab, Metronomic Chemotherapy (CM), Diet and Exercise After Preoperative Chemotherapy for Breast Cancer

Safety and Clinical Pharmacology of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Participants With Advanced Solid Tumors

A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia

Obinutuzumab in Combination With Ibrutinib in Treating Patients With Relapsed Mantle Cell Lymphoma

About this Genentech, Inc. sponsor directory page